Filtered By:
Infectious Disease: SARS
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 1917 results found since Jan 2013.
COVID-19 infection and vaccination in patients with hereditary angioedema: a multicentric study
Conclusions. Patients with HAE can safely receive COVID-19 vaccination. The severity of COVID-19 infection does not appear to be increased in HAE patients.PMID:37133310 | DOI:10.23822/EurAnnACI.1764-1489.295
Source: European Annals of Allergy and Clinical Immunology - May 3, 2023 Category: Allergy & Immunology Authors: I F da Costa Farinha M B Gaspar de Paiva Neto Freitas Tavares N A Gaspar de Sousa E Matos Marques Almeida C Lozoya Ib áñez F E de Castro Soares Regateiro A M Pego Todo-Bom Ferreira da Costa E M Antunes Gomes de Faria Source Type: research
Researchers Seek to Understand Post-COVID Autoimmune Risk Researchers Seek to Understand Post-COVID Autoimmune Risk
Three large studies link past SARS-CoV-2 infection to new-onset autoimmune disease, but it is not yet clear what drives this relationship.Medscape Medical News
Source: Medscape Allergy Headlines - May 1, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
An Action Plan for SARS-CoV-2 Infection in the Immunocompromised An Action Plan for SARS-CoV-2 Infection in the Immunocompromised
With the FDA withdrawal of Evusheld as preexposure prophylaxis against SARS-CoV-2 infection, the CDC recommends all immunocompromised persons create an action plan against COVID-19.Morbidity & Mortality Weekly Report
Source: Medscape Allergy Headlines - April 19, 2023 Category: Allergy & Immunology Tags: Public Health & Prevention Journal Article Source Type: news
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
CONCLUSION: Amubarvimab plus romlusevimab was safe and significantly reduced the risk for hospitalization and/or death among nonhospitalized adults with mild to moderate SARS-CoV-2 infection at high risk for progression to severe disease.PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases of the National Institutes of Health.PMID:37068272 | DOI:10.7326/M22-3428
Source: Annals of Internal Medicine - April 17, 2023 Category: Internal Medicine Authors: Teresa H Evering Kara W Chew Mark J Giganti Carlee Moser Mauricio Pinilla David Alain Wohl Judith S Currier Joseph J Eron Arzhang Cyrus Javan Rachel Bender Ignacio David Margolis Qing Zhu Ji Ma Lijie Zhong Li Yan Ulises D'Andrea Nores Keila Hoover Bharat Source Type: research
US National Institutes of Health Prioritization of SARS-CoV-2 Variants
Emerg Infect Dis. 2023 Apr 13;29(5). doi: 10.3201/eid2905.221646. Online ahead of print.ABSTRACTSince late 2020, SARS-CoV-2 variants have regularly emerged with competitive and phenotypic differences from previously circulating strains, sometimes with the potential to escape from immunity produced by prior exposure and infection. The Early Detection group is one of the constituent groups of the US National Institutes of Health National Institute of Allergy and Infectious Diseases SARS-CoV-2 Assessment of Viral Evolution program. The group uses bioinformatic methods to monitor the emergence, spread, and potential phenotypic...
Source: Emerging Infectious Diseases - April 13, 2023 Category: Infectious Diseases Authors: Sam Turner Arghavan Alisoltani Debbie Bratt Liel Cohen-Lavi Bethany L Dearlove Christian Drosten Will M Fischer Ron A M Fouchier Ana Silvia Gonzalez-Reiche Lukasz Jaroszewski Zain Khalil Eric LeGresley Marc Johnson Terry C Jones Barbara M ühlemann David Source Type: research
Why Did Type 1 Diabetes Rise Early in the COVID-19 Pandemic? Why Did Type 1 Diabetes Rise Early in the COVID-19 Pandemic?
Finnish investigators suggest that both increased incidence and severity at diagnosis could be related to pandemic lockdown measures rather than the SARS-CoV-2 virus itself, but other experts aren ' t sure.Medscape Medical News
Source: Medscape Allergy Headlines - April 5, 2023 Category: Allergy & Immunology Tags: Diabetes & Endocrinology News Source Type: news
Nanoparticle with mRNA appears to prevent, treat peanut allergies in mice
Key takeawaysPeanuts are one of the most common food allergens for children.UCLA scientists have developed a nanoparticle that delivers mRNA to liver cells in order to teach the immune system to tolerate peanut protein and alleviate allergies.In mice, the nanoparticle successfully dampened symptoms of serious allergy.Peanut allergies affect 1 in 50 children, and the most severe cases lead to a potentially deadly immune reaction called anaphylactic shock.Currently, there is only one approved treatment that reduces the severity of the allergic reaction, and it takes months to kick in. A group of UCLA immunologists is aiming ...
Source: UCLA Newsroom: Health Sciences - April 3, 2023 Category: Universities & Medical Training Source Type: news
